Expression analysis of TOP2A, MSH2 and MLH1 genes in MCF7 cells at different levels of etoposide resistance

Biomedicine and Pharmacotherapy

Volumn 66, Issue 1, 2012, Pages 29-35

  Kaplan, Esra ^a   Gündüz, Ufuk ^a  

^a MIDDLE EAST TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Breast cancer; Chemotherapy resistance; Etoposide

Indexed keywords

ETOPOSIDE; PROTEIN; PROTEIN MLH1; PROTEIN MSH2; RNA; TOP2A PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER RESISTANCE; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; MISMATCH REPAIR; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANALYSIS OF VARIANCE; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; HUMANS; MUTS HOMOLOG 2 PROTEIN; NUCLEAR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84856669291     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2011.09.002     Document Type: Article

References (36)

1. Liscovitch M., Lavie Y. Cancer multidrug resistance: a review of recent drug discovery research. IDrugs 2002, 5(4):349-355.
2. Gerlach J.H., Kartner N., Bell D.R., Ling V. Multidrug resistance. Cancer Surv 1986, 5(1):25-46.
3. Jeffrey M., Charles S.M., Kenneth H.C. Drug resistance and its clinical circumvention. Cancer medicine 2003, BC Decker, Hamilton (ON), [Chapter 48]. D.W. Kufe, R.E. Pollock, R.R. Weichselbaum, R.C. Bast, T.S. Gansler, J.F. Holland, E. Frei, Holland Frei (Eds.).
4. Larsen A.K., Skladanowski A. Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death. Biochim Biophys Acta 1998, 1400:257-274.
5. Fedier A., Schwarz V.A., Walt H., Carpini R.D., Haller U., Fink D. Resistance to topoisomerase poisons due to loss of DNA mismatch repair. Int J Cancer 2001, 93(4):571-576.
6. Baldwin E.L., Osheroff N. Etoposide, topoisomerase II and cancer. Curr Med Chem AntiCancer Agents 2005, 5:363-372.
7. Pitts S.L., Jablonksy M.J., Duca M., Dauzonne D., Monneret C., Arimondo P.B., et al. Contributions of the D-Ring to the activity of etoposide against human topoisomerase IIα: potential interactions with DNA in the ternary enzyme-drug-DNA complex. Biochemistry 2011, 50(22):5058-5066.
8. Liu L.F. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989, 58:351-375.
9. Burden D.A., Osheroff N. Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim Biophys Acta 1998, 1400(1-3):139-154.
10. Takano H., Kohno K., Matsuo K., Matsuda T., Kuwano M. DNA topoisomerase-targeting antitumor agents and drug resistance. Anticancer Drugs 1992, 3(4):323-330.
11. Hasegawa S., Abe T., Naito S., Kotoh S., Kumazawa J., Hipfner D.R., et al. Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines. Br J Cancer 1995, 71(5):907-913.
12. Chen A.Y., Liu L.F. DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 1994, 34:191-218.
13. Aebi S., Fink D., Gordon R., Kim H.K., Zheng H., Fink J.L., et al. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res 1997, 3:1763-1767.
14. Lage H., Dietel M. Involvement of the DNA mismatch repair system in antineoplastic drug resistance. J Cancer Res Clin Oncol 1999, 125(3-4):156-165.
15. Jacob S., Aguado M., Fallik D., Praz F. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res 2001, 61(17):6555-6562.
16. Işeri ö.D., Kars M.D., Eroĝlu S., Gündüz U. Drug resistant MCF-7 cell lines also developed cross-resistance to structurally unrelated anticancer agents. Int J Hem Oncol 2009, 19(1):1-8.
17. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCt method. Methods 2001, 25(4):402-408.
18. Di Nicolantonio F., Mercer S.J., Knight L.A., Gabriel F.G., Whitehouse P.A., Sharma S., et al. Cancer cell adaptation to chemotherapy. BMC Cancer 2005, 5:78.
19. Asano T., Nakamura K., Fujii H., Horichi N., Ohmori T., Hasegawa K., et al. Altered expression of topoisomerase IIalpha contributes to cross-resistant to etoposide K562/MX2 cell line by aberrant methylation. Br J Cancer 2005, 92(8):1486-1492.
20. Karran P. Mechanisms of tolerance to DNA damaging therapeutic drugs. Carcinogenesis 2001, 22(12):1931-1937.
21. Fink D., Aebi S., Howell S.B. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998, 4:1-6.
22. Bock N., Meden H., Regenbrecht M., Jünemann B., Wangerin J., Marx D. Expression of the mismatch repair protein hMSH2 in carcinoma in situ and invasive cancer of the breast. Anticancer Res 2000, 20(1A):119-124.
23. Boyer J.C., Umar A., Risinger J.I., Lipford J.R., Kane M., Yin S., et al. Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines. Cancer Res 1995, 55(24):6063-6070.
24. De las Alas M.M., Aebi S., Fink D., Howell S.B., Los G. Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance. J Natl Cancer Inst 1997, 89(20):1537-1541.
25. Sonoda E., Hochegger H., Saberi A., Taniguchi Y., Takeda S. Differential usage of non-homologous end-joining and homologous recombination in double strand break repair. DNA Repair (Amst) 2006, 5(9-10):1021-1029.
26. Smith J.A., Bannister L.A., Bhattacharjee V., Wang Y., Waldman B.C., Waldman A.S. Accurate homologous recombination is a prominent double-strand break repair pathway in mammalian chromosomes and is modulated by mismatch repair protein Msh2. Mol Cell Biol 2007, 27(22):7816-7827.
27. Wang Yi, Cortez D., Yazdi P., Neff N., Elledge S.J., Qin J. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 2000, 14:927-939.
28. Russell B. Interactions with topoisomerase IIα enhance the unwinding activity of the BLM helicase on recombination substrates and are necessary for preventing chromosome breakage 2002, Boston University, Masshachusetts, [PhD Thesis].
29. Miyagawa K. Clinical relevance of the homologous recombination machinery in cancer therapy. Cancer Sci 2008, 99(2):187-194.
30. Guo L., Liu X., Jiang Y., Nishikawa K., Plunkett W. DNA-PK and ATM promote cell survival in response to NK314, a topoisomerase II {alpha} inhibitor. Mol Pharmacol 2011, 80(2):321-327.
31. Chen W., Robertson J.S. The role of mismatch repair machinery in regulating mitotic and meiotic recombination between diverged sequences in yeast. Genetics 1999, 151:1299-1313.
32. Chen F., Arseven O.K., Cryns V.L. Proteolysis of the mismatch repair protein MLH1 by Caspase-3 promotes DNA damage-induced apoptosis. J Biol Chem 2004, 279(26):27542-27548.
33. Benjamin C.W., Hiebsch R.R., Jones D.A. Caspase activation in MCF7 cells responding to etoposide treatment. Mol Pharmacol 1998, 53(3):446-450.
34. Chen J., Sadowski I. Identification of the mismatch repair genes PMS2 and MLH1 as p53 target genes by using serial analysis of binding elements. Proc Natl Acad Sci U S A. 2005, 102(13):4813-4818.
35. Kars M.D. Molecular mechanisms of vincristine and paclitaxel resistance in MCF-7 cell line 2008, METU, Ankara, [PhD Thesis].
36. Işeri O.D. Investigation of docetaxel and doxorubicin resistance in MCF-7 breast carcinoma cell line 2009, METU, Ankara, [PhD Thesis].